ClinicalTrials.gg
RecruitingNCT07517354FAMESUpdated Apr 8, 2026

Family-Based Moyamoya Susceptibility and Early Detection

An observational study in Moyamoya Disease, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Beijing Tiantan Hospital · Observational

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
700
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Moyamoya Disease by Beijing Tiantan Hospital — 10 open to participants now, 10 under way, none of them phase 3. Moyamoya Disease · Beijing Tiantan Hospital.

Planned enrollment
3rd of 11
700 · median 350
Started
2024
with 2 others
Observational
11 of 14
8 open now
Registered
11th of 14
by date

Among the 14 studies in Moyamoya Disease by Beijing Tiantan Hospital, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2024, is one of 11 observational ones, and was the 11th registered.

Moyamoya Disease

62 studies on the registry are indexed under Moyamoya Disease; 30 are open to participants now.

Browse Moyamoya Disease studies →

Open to participants now

10 of the 14 studies in Moyamoya Disease by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 22 Moyamoya Disease studies recruiting now, 9 (41%) set no upper age limit and 10 (45%) stop at 75 or younger; 9 take children under 18; 5 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Moyamoya Disease by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

This single-center, prospective, family-based observational cohort study aims to investigate susceptibility to moyamoya disease (MMD) and to develop strategies for early screening in individuals at increased familial risk. The study will enroll three groups: patients with MMD, their first-degree relatives, and healthy controls without a family history of MMD.

The rationale for this study is that MMD has an important genetic component, but genetic susceptibility alone does not fully explain disease onset. Current diagnosis often relies on angiographic evaluation after symptoms have already appeared. This study seeks to identify earlier, less invasive biological and imaging markers that may help detect individuals at high risk before overt clinical disease develops.

At baseline, participants will undergo collection of demographic and clinical data, vascular risk factors, neurological assessments, routine laboratory testing, and 5T high-resolution magnetic resonance imaging. Biospecimens including blood, urine, stool, saliva, and nasal swabs will be collected for multi-omics and biomarker analyses; surgically obtained tissue specimens may also be collected from patients undergoing clinically indicated surgery.

Participants in the patient and first-degree relative groups will be followed annually for 3 years, primarily by telephone or online questionnaire, with optional repeat 5T MRI during follow-up. The primary objective is to identify baseline biological and imaging features associated with incident MMD in first-degree relatives and to establish an interpretable early-screening framework for high-risk populations.

Read the detailed description

Moyamoya disease (MMD) is a chronic, progressive cerebrovascular disorder characterized by progressive stenosis or occlusion of the terminal internal carotid arteries and their major branches, accompanied by the development of abnormal collateral vessels. Although genetic susceptibility plays an important role in MMD, incomplete penetrance suggests that non-genetic factors, including immune, inflammatory, metabolic, microbial, and environmental influences, may also contribute to disease onset and progression. Earlier identification of high-risk individuals remains challenging because definitive diagnosis is often made only after clinical symptoms appear.

This study is an investigator-initiated, single-center, prospective, non-randomized, non-interventional observational cohort study conducted at Beijing Hospital. A total of 700 participants are planned for enrollment, including 400 patients with MMD, 200 first-degree relatives of patients with MMD, and 100 healthy controls without a family history of MMD. The overall study duration is 5 years, and the expected participation time for each participant is approximately 3 years.

The main objective is to identify early biological and imaging markers of MMD and to evaluate susceptibility in individuals with familial risk. By comparing patients, unaffected first-degree relatives, and healthy controls at baseline, and by prospectively following the relative group, the study aims to determine which baseline features are associated with future disease development and to define risk factors that may support early screening strategies. The study also seeks to generate a multimodal panel of candidate markers and to build an interpretable early warning framework for high-risk populations.

At baseline, the study will collect demographic data, family history, medical history, medication use, vascular risk factors, smoking and alcohol exposure, neurological status, physiological measures, and lifestyle information. All groups will undergo routine laboratory testing and 5T high-resolution MRI at enrollment. Biospecimens will include blood, urine, stool, saliva, and nasal swabs for analyses such as inflammatory markers, metabolomics, and microbiome profiling. For patients who undergo clinically indicated surgery, operative tissue specimens may also be collected without adding surgical risk.

Follow-up will be performed once yearly for 3 years, mainly by telephone or online questionnaire, in the patient and first-degree relative groups. Participants who are willing may return for optional repeat 5T MRI. Follow-up assessments will include new diagnosis of MMD or suspected cerebrovascular events in the relative group, disease progression in the patient group, functional outcome by modified Rankin Scale, changes in symptoms and daily activity, medication changes, and control of major risk factors. If new MMD or stroke-related events are suspected, relevant medical records and imaging data will be collected for outcome adjudication.

The primary outcomes are: (1) incident MMD during follow-up in first-degree relatives, confirmed by clinical diagnosis and imaging findings; and (2) disease progression and prognosis in patients with MMD, including recurrent stroke or transient ischemic attack, rehospitalization, repeat surgery or intervention, and functional outcome. Secondary outcomes include imaging progression, cardiovascular or cerebrovascular death and all-cause mortality, and post-stroke disability defined as modified Rankin Scale score greater than 3.

The analytical strategy will include baseline cross-sectional comparisons across the three groups and longitudinal analysis of first-degree relatives according to whether MMD develops during follow-up. Candidate biomarkers and imaging features associated with future disease onset will be evaluated and integrated into prediction models using regression-based and/or machine-learning approaches, with assessment of discrimination, calibration, and potential clinical utility for early screening.

03

Conditions studied

  • Moyamoya Disease

Browse trials for

Keywords

  • Moyamoya Disease
  • Early Screening
  • Family-Based Cohort
  • Biomarkers
  • High-Resolution MRI
  • Multi-omics
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This is a single-center, family-based prospective observational cohort study conducted at Beijing Hospital. The study plans to enroll 700 participants, including 400 patients with moyamoya disease, 200 first-degree relatives of patients with moyamoya disease, and 100 healthy controls without a family history of moyamoya disease. The study population is designed to compare patients, unaffected first-degree relatives at familial risk, and healthy controls in order to identify early biological and imaging markers, evaluate disease susceptibility, and develop early screening strategies for high-risk populations.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must belong to 1 of the following 3 cohorts:

Moyamoya disease cohort: diagnosed with primary moyamoya disease according to standard diagnostic criteria, with progressive stenosis or occlusion at the terminal internal carotid arteries and/or their major branches and typical collateral vessels on DSA, CTA, or MRA; newly diagnosed and previously diagnosed cases are both eligible; no age or sex restriction.

First-degree relative cohort: first-degree blood relatives of patients with moyamoya disease, including parents, children, and siblings; no age or sex restriction; no clinical diagnosis of moyamoya disease and no history of stroke or other cerebrovascular events at enrollment; baseline MRI does not show definite moyamoya disease, although mild changes are allowed.

Healthy control cohort: no family history of moyamoya disease; no personal history of cerebrovascular disease; no major abnormalities on physical examination or baseline screening; age and sex distribution matched as closely as possible to the moyamoya disease cohort.

Exclusion criteria

Exclusion Criteria:

  • Major systemic or central nervous system diseases that may interfere with study results or substantially affect survival or adherence, such as advanced malignant tumors, active tuberculosis or other serious infections, active systemic lupus erythematosus, or severe hepatic or renal dysfunction.

Atypical cerebrovascular lesions on baseline imaging, such as widespread atherosclerotic stenosis or congenital vascular malformations.

Inability to complete examinations or follow-up, including MRI such as non-compatible metal implants or severe claustrophobia, expected difficulty completing follow-up because of long-term relocation, poor communication access, poor adherence, or other situations judged by the investigators to make participation inappropriate.

Pregnant women.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
700 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Moyamoya Disease Patients

    Participants with moyamoya disease diagnosed according to standard imaging criteria, including newly diagnosed or previously diagnosed cases. Typical findings may be identified on DSA, CTA, or MRA. This observational cohort will undergo baseline clinical assessment, routine laboratory testing, 5T high-resolution MRI, and biospecimen collection. Planned enrollment: 400.

    Diagnostic Test: 5T High-Resolution MRI

  • First-Degree Relatives of Patients With Moyamoya Disease

    First-degree blood relatives of patients with moyamoya disease, including parents, children, and siblings, without a clinical diagnosis of moyamoya disease or prior cerebrovascular events at enrollment. Baseline MRI must not show definite moyamoya disease, although mild changes may be allowed. Participants will undergo baseline assessment and annual follow-up for 3 years to identify incident moyamoya disease and early risk markers. Planned enrollment: 200.

    Diagnostic Test: 5T High-Resolution MRI

  • Healthy Controls

    Healthy participants without a family history of moyamoya disease and without a personal history of cerebrovascular disease. Participants should have no major abnormalities on baseline screening, and age and sex distribution will be matched as closely as possible to the moyamoya disease group. This observational cohort will undergo baseline clinical assessment, routine laboratory testing, 5T high-resolution MRI, and biospecimen collection. Planned enrollment: 100.

    Diagnostic Test: 5T High-Resolution MRI

Interventions

  • Diagnostic test5T High-Resolution MRI

    5T high-resolution MRI will be performed in all cohorts at baseline enrollment. During follow-up, repeat 5T MRI may be performed optionally in participants who are willing to return for imaging reassessment.

06

What researchers measure

Primary outcomes

  1. Incident Moyamoya Disease in First-Degree Relatives

    Incident moyamoya disease occurring during follow-up in first-degree relatives of patients with moyamoya disease, confirmed by clinical diagnosis and imaging findings, including computed tomography angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA).

    Time frame: From enrollment through 3 years of follow-up

  2. Recurrent Stroke or Transient Ischemic Attack in Participants With Moyamoya Disease

    Occurrence of recurrent stroke or transient ischemic attack during follow-up in participants with moyamoya disease, confirmed by clinical evaluation and imaging findings when applicable.

    Time frame: From enrollment through 3 years of follow-up

Secondary outcomes

  1. Rehospitalization in Participants With Moyamoya Disease

    Any rehospitalization related to moyamoya disease or its complications during follow-up in participants with moyamoya disease.

    Time frame: From enrollment through 3 years of follow-up

  2. Repeat Surgery or Intervention in Participants With Moyamoya Disease

    Any repeat surgical revascularization or other disease-related intervention during follow-up in participants with moyamoya disease.

    Time frame: From enrollment through 3 years of follow-up

  3. Functional Outcome Assessed by Modified Rankin Scale

    Functional outcome assessed using the Modified Rankin Scale, a 7-point scale ranging from 0 to 6, where 0 indicates no symptoms and 6 indicates death; higher scores indicate worse functional outcome.

    Time frame: At 3 years after enrollment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Individual participant data sharing is currently undecided. The study involves longitudinal clinical, imaging, biospecimen, and multi-omics data from patients with moyamoya disease, first-degree relatives, and healthy controls. Any future sharing of de-identified individual participant data will depend on institutional policy, ethics committee approval, participant consent, data privacy protection, and the development of an appropriate data access mechanism.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Nov 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2026
First posted
Apr 8, 2026
StartActual
Nov 12, 2024
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2030
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07517354
Responsible party
Dong Zhang (Chief physician, Beijing Hospital) — Principal investigator
First posted
Apr 8, 2026
Start date
Nov 12, 2024
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2030 (estimated)
Last update
Apr 8, 2026

Study contacts

Dong Zhang, MD
Contact
zhangdong0660@aliyun.com
+86-13801121292

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion